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ABSTRACT Recombinant factor VIa (rF.VIIa) is a two-
chain procoagulant enzyme (Mr, =50,000) active only when
complexed with tissue factor in the extrinsic clotting system.
We administered human rF.VIIa to hemophilic and von
Willebrand disease (vWD) dogs to determine its hemostatic
effectiveness and survival in the circulation. Hemophilia A dogs
lacking factor VIII demonstrated an immediate increase in
plasma rF.VIIa and prompt stoppage of hemorrhage at bleed-
ing time (BT) sites. In seven studies in two dogs, the range of
dose of rF.VIIa was 50-220 ,ug/kg, with an apparent 7- to
11-fold increase in plasma factor VII and a mean recovery in
plasma of 34%. The til2 was 2.8 ± 0.5 hr. The BT was
normalized except in an animal given the minimum dose. In
four studies in two hemophilia B dogs lacking factor IX, BT was
normalized. The elevation in plasma factor VII was by a factor
of 8-30, with a mean recovery of rF.VIIa in plasma of 44%. In
two studies in a homozygous vWD dog lacking von Willebrand
factor, which is needed for platelet function, BT was not
corrected even though large doses of rF.VIIa were given. The
human rF.VIIa protein was immunogenic for dogs. These
studies indicate that factor VIa corrects the hemostatic defect
in dogs with hemophilia A and B, diseases primarily of the
intrinsic clotting system, but does not correct the hemostatic
defect in vWD.
The pathophysiology of hemophilia A and hemophilia B is
determined by the lack of specific plasma procoagulant
proteins, factors VIII and IX, respectively. In each disease,
there is impairment of the intrinsic pathway of coagulation,
with inadequate thrombin generation and defective hemosta-
sis. Infusions of the missing protein correct the hemostatic
defect except when an alloantibody has developed that
neutralizes the antihemophilic factor (inhibitor hemophilia).
It has long been recognized that the extrinsic pathway of
coagulation involving tissue factor (TF) and factor VII may
also be impaired in hemophilia A (1). It was demonstrated 50
years ago that the very slow thrombin generation in hemo-
philic blood can be corrected by addition of small amounts of
TF-i.e., thromboplastin (2), the TF effect being dose de-
pendent. If only a trace of TF is used, the clotting of both
human and canine hemophilic plasma remains long (3). This
is the basis of the dilute thromboplastin time test for hemo-
philia, in which factor VII appears to be incompletely
activated to form factor VIa (4). The prolonged dilute
thromboplastin time in hemophilia, while not completely
understood, may be due to impaired factor VII activation in
this disease (5), possibly the result of lack of factor VIII or IX
(6). Normally factor VIIa, complexed with TF, forms the
active enzyme that converts factor X to Xa, which in turn
converts prothrombin to thrombin in the presence of factor
Va. The complex also converts factor IX to factor IXa (7),
thus representing a link between the intrinsic and extrinsic
pathways. The mechanism of action of TF and factor VII has
been reviewed (8, 9).
Additional evidence for a possible role of the extrinsic
system in hemophilia came from infusing plasma concen-
trates containing the activated procoagulant enzymes, fac-
tors IXa, Xa, and VIla, to "bypass" the defect in inhibitor
hemophilia. Such concentrates had a hemostatic effect, but
thrombosis was observed with higher dosage (10, 11). The
purification of factor VII from plasma (12) allowed prelimi-
nary testing of isolated human factor VIa in microgram
amounts in inhibitor hemophilia. The results pointed to this
procoagulant as an active bypassing agent (13). Recently,
human factor VII has been cloned and expressed in mam-
malian cells (14), making it possible to produce this trace
protein in larger amounts than heretofore. During purifica-
tion, recombinant factor VIIa (rF.VIIa) is formed and is
composed of two polypeptide chains (Mr, -20,000 and
-30,000).
The studies reported here were conducted to test the
hypothesis that when sufficient rF.VIIa is introduced into the
circulation in hemophilia, the hemostatic defect can be
corrected without causing systemic coagulation. This hy-
pothesis is based on several prior findings. (i) No specific
plasma inhibitor for factor VII has been identified (15-17);
hence, rF.VIIa should not be cleared rapidly from the
circulation. (ii) Lacking TF, the rF.VIIa will be inactive in the
circulation. (iii) At the site of an injury, such as a bleeding-
time (BT) wound, TF is generated as a cell-membrane
receptor for factor VIla, and the factor VIIa-TF complex
forms promptly. The complex then initiates the extrinsic
pathway of coagulation (1, 18, 19). (iv) The onset of extrinsic
coagulation with rapid formation of fibrin in BT wounds is
normal in hemophilia (20). Supplemental rF.VIIa in hemo-
philia could result in sufficient thrombin generation with
fibrin formation and platelet activation to facilitate formation
of a stable hemostatic plug.
MATERIALS AND METHODS
Hemophilic and von Willebrand Disease (vWD) Dogs. The
subjects used for testing rF.VIIa were from the inbred Chapel
Hill colonies of hemophilia A (21, 22), hemophilia B (23), and
vWD (24) dogs. The hemophilic animals were either hemi-
zygous or homozygous, and the vWD dog was homozygous.
All were severe bleeders.
Factor Vila Preparations. rF.VIIa was obtained from baby
hamster kidney cell culture transfected with human factor
VII genomic material as described (14). The rF.VIIa was
purified from the culture medium by a four-step procedure
Abbreviations: BT, bleeding time; mAb, monoclonal antibody;
rF.VlIa, recombinant factor VIla; PTT, partial thromboplastin time;
APTT, activated PTT; TF, tissue factor; vWD, von Willebrand
disease; vWF, von Willebrand factor.
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including three ion-exchange chromatography steps and
immunoadsorption on a Sepharose 4B column (Pharmacia) to
which a monoclonal antibody (mAb) against human plasma
factor VII was coupled. On SDS/gel electrophoresis, unre-
duced samples revealed a single band; reduced samples
revealed two bands, corresponding to the light and heavy
chains of factor VIa. The specific activity was 39 units/,ug.
The rF.VIIa was provided frozen (-70°C) in 1- or 2-ml vials
(1 ml contained 0.6 mg of protein, equivalent to 23,600 units
of rF.VIIa).
Tests for Factor VII. A modified one-stage factor VII
clotting assay with rabbit brain thromboplastin and a normal
dog plasma standard were used (25). Factor VII-deficient
plasma for substrate was prepared from normal human
plasma by immunoadsorption using a mAb raised against
plasma-derived factor VII. Factor VII antigen in plasma was
determined by a double monoclonal ELISA, using two mAbs
directed against different epitopes on the factor VII molecule.
One mAb, the catching antibody, was bound to the microtiter
plate and the test plasma was added. After addition of the
second mAb, an immunoperoxidase-labeled anti-mouse IgG
was used. The mAb did not cross-react with canine factor
VII. Human plasma was used as a standard.
Other Coagulation Assays. Factor VIII:C assays were
performed by a modified one-stage method (3) using a
kaolin-activated procedure with canine hemophilia A plasma
as substrate. Factor IX assays were done with the same
procedure, using canine hemophilia B plasma as substrate.
Partial thromboplastin time (PTT) determinations were per-
formed essentially as described (3). The activated partial
thromboplastin time (APTT) determinations were performed
by using an APTT reagent (Pacific Hemostasis, Ventura,
CA), following the manufacturer's directions. Dilute throm-
boplastin time tests (3) were performed with a rabbit brain
thromboplastin reagent (Sigma Diagnostics) diluted to 1:
25,000 in 0.154 M NaCl. The procedure was a three-part test
consisting of 1 part each of undiluted citrated plasma and
dilute thromboplastin incubated 3 min at 37°C. The clotting
time was determined after the addition of 1 part 0.025 M
CaCl2. von Willebrand factor (vWF) assays were done with
botrocetin using the macroscopic tap-tube procedure with
Iyophilized human platelets (26, 27). A group of assays was
performed to monitor for evidence of disseminated intravas-
cular coagulation following infusions of rF.VIIa. Fibrinogen
levels were determined by a syneresis method (28). Fibrin-
ogen degradation products were measured by the Thrombo-
Wellcotest (Wellcome Diagnostics), following the manufac-
turer's instructions. The ethanol gelation test was performed
by a standard method (29). Platelet counts were done by the
Unopette microcollection method (Becton Dickinson).
Antibody Assays. Bleeder dog plasmas were assayed for
antibodies against injected human factor VIla with an ELISA
method as follows: rF.VIIa was bound on the ELISA plate,
test plasma was added, and a peroxidase-conjugated rabbit
anti-canine IgG (Nordic, Tilburg, The Netherlands) was used
as a detecting antibody. Normal dog plasma served as a
negative control.
Infusions of rF.VIIa. rF.VIIa (2-15 ml) was infused via the
jugular vein into hemophilia A, hemophilia B, and vWD dogs.
Blood sampling was done immediately before infusion and at
intervals up to 24 hr postinfusion. Citrated plasma samples
were frozen in 0.2-ml aliquots at -70°C within 20 min ofblood
collection. The expected levels of plasma factor VIIa antigen
were calculated on the basis of dose and an assumed plasma
volume of 5% of body weight. Half-life (til) values of infused
rF.VIIa were determined in hemophilia A dogs (Exps. 5-7)
by linear-regression analysis after transformation of factor
VII (units/ml) and factor VII antigen (ng/ml) values into
natural logarithmic values. Blood samples were collected at
10 min, 1, 3, and 6 hr. The ti/2 is In 2/slope of the regression
line. In normal dogs, the til, for factor VII was 2.3 ± 0.12 hr and
for factor VII antigen it was 2.8 ± 0.04 hr.
Hemostatic Testing. A modified toenail BT test, as de-
scribed (22, 30), was used for the hemophilic dogs. The saline
BT test on the ear (31) was used for the vWD dog.
RESULTS
Response of Hemophilia A and Hemophilia B Dogs to Infused
rF.VIIa. Seven infusions of rF.VIIa were given to two
hemophilia A dogs (Table 1, Exps. 1-7). The dose of rF.VIIa
varied from 49 to 219 ,ug per kg of body weight. The expected
and actual plasma levels of factor VIla antigen immediately
postinfusion indicate a mean retention in the circulation of
34% ± 13% of the injected dose, with a range of 18% to 48%.
The plasma levels of factor VII were elevated from 4- to
11-fold above preinjection values. The fall-offs of plasma
factors VII and VII antigen are illustrated in Fig. 1A. At 24
hr, the levels of these factors had returned to preinfusion
values. The ti12 for factor VII was 2.1 + 0.6 hr and for factor
VII antigen it was 2.8 ± 0.5 hr. The postinfusion BT was
Table 1. Infusion of recombinant human factor VI~a into hemophilia A, hemophilia B, and vWD dogs
Plasma F.VII 10 min postinfusion
rF.VIIA dose Expected One-Dog Total, antigen, Antigen, stage, PTT, sec Secondary BT, min
Exp. No. Disease Day* mg ug/kg ng/ml ng/ml units/ml Base 10 min Preinfusion Postinfusion
1 1 Hem A 2 0.7 49 993 450 7.2 55 42 >15 11.0
2 1 Hem A 0 0.85 60 1,206 512 7.3 52 43 >15 3.0
3 1 Hem A 1 0.85 60 1,206 473 7.9 54 44 >15 3.Ot
4 1 Hem A 5 3.1 219 4,397 1210 9.4 52 46 >15 1.5
5 2 Hem A 0 1.17 64 1,277 228 3.7 64 48 >15 2.0
6 2 Hem A 1 2.78 51 3,016 545 8.1 58 30 >15 2.0
7 2 Hem A 2 3.55 193 3,859 1867 11.2 59 35 >15 1.5t
8 3 Hem B 3 1.25 67 1,344 468 8.3 78 46 >15 2.5
9 3 Hem B 1 3.65 196 3,925 1810 14.0 49 34 >15 4.Ot
10 3 Hem B 0 3.7 199 3,978 1813 30.7 69 36 >15 2.0
11 4 Hem B 0 2.5 153 3,067 1490 22.9 60 37 >15 2.5
12 5 vWD 0 3.5 257 5,147 2855 42.5 33 30 ND >15t
13 5 vWD 1 7.5 550 11,029 4925 64.0 33 25 ND >15t
Hem, hemophilia; ND, not done.
*Day after first infusion for each dog.
tSecondary cuticle BT initiated 3 min before rF.VIIa.
tEar BT.
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B infusion of a sufficient amount of rF.VIIa without induction
of a systemic clotting reaction.
Four infusions of rF.VIIa were given to two hemophilia B
animals (Table 1, Exps. 8-11). The range of dose of rF.VIIa
was 67-199 pg/kg. The postinfusion plasma levels of factor
VII were increased 8.3-30.7 units/ml. The mean postinfusion
recovery of rF.VIIa antigen in the plasma was 44% ± 6%.
These values were higher than in the hemophilia A dogs with
comparable doses of rF.VIIa. The correction of the hemo-
static defect was similar to that observed in the hemophilia A
dogs. Fig. 1B provides data illustrating the loss over time of
the effect of rF.VIIa infusions. The basal values for the PTT
and the APTT tests were longer in the hemophilia B dogs than
in those with hemophilia A, and both tests were shortened
after rF.VIIa infusions. The tests for systemic clotting were
negative. Plasma factor IX was undetectable throughout the
experiments. These data indicate that the hemophilia B dogs,
like the hemophilia A animals, respond to rF.VIIa infusions
by correction of the hemostatic defect and without evidence
of systemic coagulation.
Effect of rF.VIIa on in Vitro Clotting ofHemophilic Plasmas.
In view of the shortening of both the PTT and the dilute
thromboplastin time in hemophilia A and hemophilia B dogs
given rF.VIIa, the effect of adding rF.VIIa in vitro on the
prolonged clotting time of the hemophilic plasmas in these
tests was determined. Fig. 2 illustrates the progressive
shortening of hemophilia A and hemophilia B plasmas with
increasing concentrations of rF.VIIa. The highest concen-
tration of rF.VIIa corresponds to -70 units of factor VII per
ml. Higher concentrations of rF.VIIa up to 500 units/ml
reduced the PTT to a minimum of =20 sec for both plasmas.
Fig. 3 depicts similar data on the effect of rF.VIIa on the
dilute thromboplastin time. Hemophilia B plasmas consis-
tently exhibited a longer clotting time with these tests than
did hemophilia A plasmas. Semilogarithmic plots of the data
(not shown) demonstrated a linear relationship between
rF.VIIa concentration and clotting time in each of the tests.
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FIG. 1. Effect of infusions of rF.VIIa to hemophilia A (A) and
hemophilia B (B) dogs on plasma factor VII, factor VII antigen, PTT,
and toenail BT. Arrows indicate time of rF.VIIa administration.
Illustrations of infusions in a hemophilia A dog (Table 1, Exp. 7;
dose, 193 ,ug/kg) and a hemophilia B dog (Table 1, Exp. 9; dose, 1%
,.g/kg).
shortened to the normal range of <5 min except in Exp. 1, in
which a low dose of rF.VIIa was administered. At 6 hr
postinfusion (Fig. 1A), the BT had returned to basal levels,
although in a few experiments a shortened BT was still noted.
Both the activated and unactivated PTTs were determined at
intervals before and after rF.VIIa infusions. The APTT
values were affected very little by the infusions. In contrast,
the PTT values were considerably shortened (Table 1). Some
shortening of the PTT persisted at 6 hr but not at 24 hr (Fig.
1A). The various assays used as indicators of systemic
intravascular clotting were unchanged from basal conditions,
with one exception. In Exp. 4, conducted on the 5th day after
the first rF.VIIa injection, the ethanol gelation test was
negative for gelation but did demonstrate flocculation. A
plasma sample collected on day 6 demonstrated low-titer
anti-factor VII antibody. Plasma factor VIII remained at
<1%. Collectively, these experiments suggest an immediate
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FIG. 2. Acceleration of the PTT of hemophilic plasmas on
addition of rF.VIIa. The rF.VIIa (1 part) was added to hemophilic
plasma (9 parts). The test mixture consisted of equal parts of partial
thromboplastin reagent (Thrombofax, Ortho Diagnostics), citrated
hemophilic plasma with rF.VIIa, and 0.025 M CaCl2. The values on
the abscissa represent the concentration of rF.VIIa in the plasma.
Curve A, canine hemophilia A plasma; curve B, canine hemophilia
B plasma.
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FIG. 3. Acceleration of the dilute thromboplastin time on
addition of rF.VIIa to hemophilic plasmas. The rF.VIIa (1 part) was
added to hemophilic plasma (9 parts). The test mixture consisted of
equal parts of dilute rabbit brain thromboplastin reagent, citrated
hemophilic plasma with rF.VIla, and 0.025 M CaCl2. Curve A,
canine hemophilia A plasma; curve B, canine hemophilia B plasma.
Response of a vWD Dog to Infused rF.VIIa. Two infusions
were given to a vWD animal. The doses of rF.VIIa were
considerably larger than those given to the hemophilic
animals, and the increase in plasma levels of factor VII and
factor VII antigen was correspondingly greater (Table 1,
Exps. 12 and 13). The mean recovery of factor VII antigen
immediately postinfusion was 40%. There was no corrective
effect on the long BT.
Immunologic Response of Bleeder Animals to Human
rF.Vlla. A transient urticarial-type reaction lasting for -30
min occurred on only one occasion in four of the five bleeder
animals within 10 min following the injection of rF.VIIa
(Table 1, Exps. 7, 10-12). Wheals appeared most promi-
nently about the face.
Anti-human factor VII antibodies were detected in the
plasmas of all animals 1-2 wk after the animals received the
first dose of rF.VIIa. The response of the animals varied and
appeared unrelated to the dose of rF.VIIa. Dog 2 was a low
responder, with antibody being detected in the 2-wk sample
only (titer, 1:100). The remaining dogs had a maximum titer
of 1:1000. The antibody persisted for 10 wk in dogs 3 and 4,
and for 22 and 29 wk in dogs 5 and 1, respectively.
DISCUSSION
The availability of rF.VIIa permitted the testing of its
hemostatic properties over a wide range of dosages in the two
hemophilic diseases, canine hemophilia A and B. The recip-
ient's plasma levels of factor VII were elevated many times
the physiological amounts. The secondary toenail BT test
was used as the hemostatic test, since the primary toenail BT
is normal in hemophilic dogs (3-5 min). The secondary BT
was performed by shaving off the clot at the primary site to
restart bleeding. In hemophilic subjects, the secondary BT is
>15 min; in normal animals, it is <5 min (22). The design of
the experiments was to test the effect of rF.VIIa in two ways:
(i) infusion before the secondary BT was done-i.e., preven-
tion of prolonged bleeding and (ii) infusion while the nail was
actively bleeding-i.e., stanching of bleeding in progress.
With each schedule the defective hemostasis in both types of
hemophilia was immediately corrected by infusions of similar
doses of rF.VIIa. These events suggest that activation of
factor IX by the rF.VIIa-TF complex is not essential for its
hemostatic effect in hemophilia. The two hemophilic diseases
are due to a deficiency of different proteins that act in a
different manner in the intrinsic coagulation pathway. The tl2
of injected rF.VIIa in these experiments was in the 2- to 3-hr
range, similar to that observed in inhibitor hemophilia A
patients given clinical factor IX concentrates (32). The
administration of rF.VIIa in excess seems to induce normal
hemostasis in the hemophilic dogs, bypassing the activation
of factor IXa and perhaps activation of factor VII as well.
Determination of plasma factor VII levels after rF.VIIa
infusions can be made with either the factor VII bioassay or
immunoassay procedures. Both the PTT and the dilute
thromboplastin time tests appear to be suitable for monitoring
changes in plasma rF.VIIa levels. The clotting times in these
tests are prolonged in hemophilia A and B and are shortened
by infusions of rF.VIla in the hemophilic dogs (Fig. 1) or by
addition of rF.VIIa in vitro to their plasmas (Figs. 2 and 3).
The unactivated PTT was more sensitive to changes in
plasma concentration of rF.VIIa than was the activated test.
The sensitivity of the dilute thromboplastin time to rF.VIIa
is probably due to the presence of TF in the thromboplastin
reagent, giving rise to the TF-rF.VIIa complex. The question
raised was whether the sensitivity of the PTT test to rF.VIIa
could be due to some unrecognized source of TF in the
reagents or whether it was independent of the availability of
TF. A limited survey for TF was made in the PTT reagents.
The lipid PTT reagent made from cow brain was tested in an
ELISA procedure with a mAb specific for bovine TF (HTF1-
788) (33), using Thrombotest (Nycomed, Oslo) reagent also
made from cow brain as a positive control. The PTT reagent
was negative for TF. A second mAb, an anti-human TF (34)
that cross-reacts with canine TF, was used to test canine
hemophilic plasmas. They were weakly positive. Further
study of this question is needed.
Infusions of the human rF.VIIa protein into the dogs
elicited an immediate urticarial response in 4 of the 11
experiments. Only one animal escaped this reaction. All of
the animals developed antibodies against rF.VIIa. One of the
animals was a low responder. Similar findings have been
reported following administration of human factor VIII
preparations to hemophilia A dogs (35).
The hemostatic defect in the vWD dog was not corrected
by infusions of rF.VIIa in spite of the fact that very large
doses were administered. The defect in these animals is
severe and is due primarily to defective platelet adhesion and
agglutination resulting from the absence of vWF. The vWD
animal is a model for type III human vWD or homozygous
type I vWD (36). vWF appears to be essential for the
development of the platelet component of thrombi. Admin-
istration of a monoclonal anti-vWF has been shown to
prevent development of an arterial thrombus in normal pigs
(37), which correlates with the inability of homozygous vWD
subjects to form a hemostatic plug. These data suggest that
forced thrombin generation with rF.VIIa will not compensate
for the lack of vWF and vWF platelet function. Thrombin
activation of platelets is mediated through the glycoprotein
HIb/Ila receptor. vWF binds to both this receptor and to
glycoprotein lb. These and other findings suggest that the
vWF-glycoprotein lb pathway is an essential one for hemo-
static plug formation (37, 38). rF.VIIa needs to be tested in
other types of vWD in which some vWF is present. Under
these conditions with limited vWF, rF.VIIa may promote
hemostasis.
Note Added in Proof. Since this manuscript was prepared, Thim et al.
(39) have published on the analysis of human factor VIa.
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